Annexin Pharmaceuticals AB (OSTO:ANNX) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Annexin Pharmaceuticals AB Debt-to-Equity?

Annexin Pharmaceuticals AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Annexin Pharmaceuticals AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Annexin Pharmaceuticals AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr6.35 Mil. Annexin Pharmaceuticals AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Annexin Pharmaceuticals AB's Debt-to-Equity or its related term are showing as below:

OSTO:ANNX' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.3 Med: 0.02 Max: 15.75
Current: 1.58

During the past 9 years, the highest Debt-to-Equity Ratio of Annexin Pharmaceuticals AB was 15.75. The lowest was -7.30. And the median was 0.02.

OSTO:ANNX's Debt-to-Equity is ranked worse than
93.35% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:ANNX: 1.58

Annexin Pharmaceuticals AB Debt-to-Equity Historical Data

The historical data trend for Annexin Pharmaceuticals AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexin Pharmaceuticals AB Debt-to-Equity Chart

Annexin Pharmaceuticals AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

Annexin Pharmaceuticals AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	15.75	-	-

Competitive Comparison of Annexin Pharmaceuticals AB's Debt-to-Equity

For the Biotechnology subindustry, Annexin Pharmaceuticals AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annexin Pharmaceuticals AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexin Pharmaceuticals AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Annexin Pharmaceuticals AB's Debt-to-Equity falls into.

Annexin Pharmaceuticals AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Annexin Pharmaceuticals AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	18.814
	=	0.00

Annexin Pharmaceuticals AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	6.346
	=	0.00

Annexin Pharmaceuticals AB (OSTO:ANNX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Annexin Pharmaceuticals AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Annexin Pharmaceuticals AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Annexin Pharmaceuticals AB (OSTO:ANNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexin Pharmaceuticals AB (OSTO:ANNX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

Q91:Germany

Address

Norrtullsgatan 6, Stockholm, SWE, SE-113 29

Website

https://www.annexinpharma.com

Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.